Previous 10 | Next 10 |
home / stock / dxcm / dxcm articles
DexCom Inc’s (NASDAQ: DXCM) Stelo Glucose Biosensor System has been approved by the Food and Drug Administration (FDA) as the first over-the-...
On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named SL Green Realty Corp. (NYS...
Tuesday, the FDA approved DexCom Inc’s (NASDAQ:DXCM) Stelo Glucose Biosensor System as the first over-the-counter (OTC) contin...
With U.S. stock futures trading mostly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: Wall...
Thursday, after-hours Dexcom Inc (NASDAQ:DXCM) reported fourth-quarter 2023 earnings with sales of $1.03 billion, up 27% Y/Y (+26% on an ...
DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 26.47% on an annualized basis producing an average annual return of 39.0...
DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 28.38% on an annualized basis producing an average annual return of 40.5...
DexCom (NASDAQ:DXCM) has outperformed the market over the past 15 years by 30.7% on an annualized basis producing an average annual return of 42.6%...
DexCom (NASDAQ:DXCM) has outperformed the market over the past 5 years by 19.36% on an annualized basis producing an average annual return of 30.98...
News, Short Squeeze, Breakout and More Instantly...
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the...
The world’s most connected continuous glucose monitoring system ‡ , Dexcom G6, now connects with the Omnipod® 5 Automated Insulin Delivery (AID) System in The Netherlands. DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring fo...